Details of the Drug
General Information of Drug (ID: DMZ8PBE)
| Drug Name |
6beta-naltrexol HCl
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL558140; UNII-765G11MG24; 765G11MG24; 55488-86-3; Naltrexone metabolite 6; A-Naltrexol (hydrochloride); 6beta-Naltrexol hydrochloride; HY-G0019; 6beta-Hydroxynaltrexone hydrochloride; Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, hydrochloride, (5alpha,6beta)-; Naltrexone metabolite 6AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Naltrexol (hydrochloride)
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 |
Molecular Weight | 379.9 | |||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||
| Rotatable Bond Count | 2 | ||||||||||||||||||
| Hydrogen Bond Donor Count | 4 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count | 5 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


